Hair repigmentation associated with thalidomide use for the treatment of multiple myeloma

BMJ Case Reports

Volumn 2016, Issue , 2016, Pages

  Lovering, Stephanie ^a   Miao, Wenya ^a   Bailie, Toni ^a   Amato, Dominick ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BUDESONIDE PLUS FORMOTEROL; CYCLOPHOSPHAMIDE; DALTEPARIN; DILTIAZEM; DOXORUBICIN; INDAPAMIDE; LEVOTHYROXINE; MELPHALAN; MULTIVITAMIN; PACLITAXEL; PAMIDRONIC ACID; PARAPROTEIN; PREDNISONE; RANITIDINE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; ANGIOGENESIS INHIBITOR;

AGED; ANEMIA; ARTICLE; ASTHMA; BONE LESION; BONE MARROW BIOPSY; BREAST CANCER; CASE REPORT; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAIR DISEASE; HAIR REPIGMENTATION; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTHYROIDISM; LONG TERM CARE; MAINTENANCE THERAPY; MASTECTOMY; MIGRAINE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOPENIA; PERIPHERAL NEUROPATHY; PIGMENT DISORDER; PRIORITY JOURNAL; TREATMENT OUTCOME; DRUG EFFECTS; HAIR COLOR;

AGED; ANGIOGENESIS INHIBITORS; FEMALE; HAIR COLOR; HUMANS; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 84979516817     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2016-215521     Document Type: Article

References (12)

1. Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011;118:1239-47.
2. Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther 2003;25:342-95.
3. Dasanu CA, Mitsis D, Alexandrescu DT. Hair repigmentation associated with the use of lenalidomide: graying may not be an irreversible process! J Oncol Pharm Practice 2013;19:165-9.
4. Trüeb RM, Tobin D. eds. Aging hair. Berlin, Heidelberg: Springer-Verlag, 2010.
5. Slominski A, Wortsman J, Plonka PM, et al. Hair follicle pigmentation. J Invest Dermatol 2005;124:13-21.
6. Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol 2008;27:111-35.
7. Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 2001;115:881-94.
8. Choe JY, Jung HJ, Park KY, et al. Anti-fibrotic effect of thalidomide through inhibiting TGF-ß-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm Res 2010;59:177-88.
9. Tintle SJ, Dabade TS, Kalish RA, et al. Repigmentation of hair following adalimumab therapy. Dermatol Online J 2015;21: pii: 13030/qt6fn0t1xz.
10. van Beek N, Bodó E, Kromminga A, et al. Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation. J Clin Endocrinol Metab 2008;93:4381-8.
11. Redondo P, Guzmán M, Marquina M, et al. Repigmentation of gray hair after thyroid hormone treatment. Actas Dermosifiliogr 2007;98:603-10.
12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.